BLS Pharmaceuticals Limited · ASX:BLS
BLS Pharmaceuticals — Bell Potter Healthcare Conference 2026
14 slides from BLS Pharmaceuticals's conference presentation, Nov 19, 2026
Slide 1: An International Pharmaceutical Manufacturing Platform
r personal use only An International Pharmaceutical Manufacturing Platform Corporate Presentation Bell Potter Healthcare Conference November 2026 | ASX: BLS
Slide 2: Disclaimer
DISCLAIMER r personal use only This presentation (Presentation) has been prepared by BLS Pharmaceuticals Limited ABN 97 084 464 193 No party other than BLS has authorised or caused the issue, lodgement, submission, dispatch or provision (BLS or the Company). The information in this Presentation is o
Slide 3: BLS at a Glance
BLS AT A GLANCE r personal use only PURPOSE PEOPLE PROFIT Creating value for all stakeholders Delivering profitable growth and positive Manufacturing innovative medicines including patients, prescribers, cash flow. We continue to invest, scale for global unmet clinical needs from pharmacies, employe
Slide 4: Investment Highlights
INVESTMENT HIGHLIGHTS r personal use only Six reasons BLS is positioned for continued profitable growth. Regulated license stack 1 GMP manufacturer licensed by the TGA, ODC and QLD Health across cannabis, MDMA and psilocybin. Licenses, GMP know-how and scale create high barriers to entry. Profitable
Slide 5: Leader in the Profitable Part of the Value Chain
LEADER IN THE PROFITABLE PART OF THE VALUE CHAIN r personal use only BLS PHARMACEUTICALS Raw Active PHARMACEUTICAL WHOLESALE / Pharmacy / Prescribing Patient Materials Pharmaceutical MANUFACTURING DISTRIBUTION Dispensary Physician (Cultivators of Ingredients Mushrooms, (API) Cannabis) Licensed Licen
Slide 6: Market Opportunity
MARKET OPPORTUNITY r personal use only Industry investment and regulatory tailwinds across BLS end markets. RECENT PHARMACEUTICAL AND CANNABIS SECTOR REGULATORY & MARKET DEVELOPMENTS TRANSACTIONS Eli Lilly / AtaiBeckley NSW medicinal cannabis driving Driving law reforms passed in 2026, with Acquisit
Slide 7: A Track Record of Growth
A TRACK RECORD OF GROWTH r personal use only Revenue up 14x from FY23 to FY26, with FY27 guidance of $105m to $115m. REVENUE ($ MILLION) 14x $105m to $115m REVENUE GROWTH FY23 to FY26 $74.2m +161% FY26 REVENUE GROWTH vs FY25 $28.4m $9.3m Q1 FY27 $5.2m $26.7m +42% to +55% FY23 FY24 FY25 FY26 FY27 gui
Slide 8: Profitable Growth
PROFITABLE GROWTH r personal use only FY26 net profit after tax of $15.4m, up from $4.9m in FY25. FY26 STATUTORY FINANCIAL SUMMARY ADJUSTED EBITDA³ ($ MILLION) FY26 FY25¹ $19.0 Revenue $74.2m $28.4m m +171% Adj. EBITDA growth Profit before tax $15.2m $4.9m Net profit after tax² $15.4m $4.9m $7.0 Bas
Slide 9: A Record Start to FY27
A RECORD START TO FY27 r personal use only Q1 FY27 revenue of $26.7m, the highest quarter in BLS's history, up 91% on pcp. QUARTERLY REVENUE ($ MILLION) CASH RECEIPTS FROM CUSTOMERS $22.4m Q1 FY26: $12.9m $26.7m $21.7m NET OPERATING CASH FLOW $21.3m $17.2m $2.0m Q1 FY26: ($4.1m) $14.0m CASH AT 30 SE
Slide 10: International Expansion
INTERNATIONAL EXPANSION r personal use only Current supply, contracted supply and infrastructure in development. SUPPLYING NOW CONTRACTED IN DEVELOPMENT Australia ADREXpharma, Germany Scotland GMP facility Brisbane GMP facility supplying 130+ Two-year supply agreement valued at Progressing toward re
Slide 11: Summary - FY27 Outlook and Priorities
SUMMARY - FY27 OUTLOOK AND PRIORITIES r personal use only A record first quarter, with full-year guidance reaffirmed. FY27 GUIDANCE REAFFIRMED Execute contracted Fill existing capacity supply FY27 REVENUE Increase volumes through the Brisbane Deliver the ADREXpharma agreement, facility, where estima
Slide 12: Board and Management Team
BOARD AND MANAGEMENT TEAM r personal use only Pharmaceutical operations, capital markets and governance experience. Anthony Ho Samuel Watson Jason Hine Edward Myer Angus Walker Guy Robertson Paul Mitchell Independent Non- Managing Director & Executive Director & Non-Executive Alternate Director to C
Slide 13: Corporate Snapshot
CORPORATE SNAPSHOT r personal use only CAPITAL STRUCTURE ( as at 13 Nov em ber 20 26 ) SHAREHOLDERS Share price $0.855 Shares on issue 236,067,859 Directors Other Options and performance rights 8.4m 31% 30% Market capitalisation $201.8m Cash* $13.3m Other Top 20 69% 70% Financial debt* $3.0m Lease l
Slide 14: Contact
r personal use only CONTACT BLS Pharmaceuticals Limited Sam Watson Chief Executive Officer hello@blspharma.com James Tracey GM Corporate Development and Investor Relations jamestracey@blspharma.com NWR Communications Melissa Tempra Media & Investor Relations melissa@nwrcommunications.com.au
BLS Pharmaceuticals — Bell Potter Healthcare Conference 2026 on 6ix